Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers

Enregistré dans:

Détails bibliographiques
Publié dans:	bioRxiv (Feb 5, 2025)
Auteur principal:	Mohamad Ali Najia
Autres auteurs:	Jha, Deepak Kumar, Zhang, Cheng, Benoit, Laurent, Schuster-Kubaczka, Caroline, Markel, Arianna, Li, Christopher, Morris, Vivian, Tompkins, Allison, Hensch, Luca, Qin, Yue, Chapuy, Bjoern, Yu-Chung, Huang, Morse, Michael, Marunde, Matthew, Vaidya, Anup, Gillespie, Zachary, Howard, Sarah, North, Trista, Dominguez, Daniel, Michael-Christopher Keogh, Schlaeger, Thorsten, Yang, Shi, Hu, Li, Shipp, Margaret, Blainey, Paul, Daley, George Q
Publié:	Cold Spring Harbor Laboratory Press
Sujets:	Merck & Co Inc Cancer Transcriptomes Polychlorinated biphenyls > PCB Cytotoxicity DNA biosynthesis Heterochromatin Phenotypic plasticity Patent applications Histones Gene regulation Chromatin Epigenetics Transcription Zinc finger proteins Biochemical analysis Equity Optics Transcription activation DNA damage Nucleosomes Lymphoma Lymphocytes B B-cell lymphoma Cancer therapies
Accès en ligne:	Citation/Abstract Full text outside of ProQuest
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!